VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LKFT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LKFTLakefront Biotherapeutics N.V.
$34.39$2.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLKFTBalance Sheet

Lakefront Biotherapeutics N.V. (LKFT) Balance Sheet

22Y historyFree accessUpdated daily

Leverage is minimal with total debt of only $3.2M and a debt-to-equity ratio near zero, though the sharp equity rebuild to $3.3B appears tied to the 2025Q4 earnings spike rather than steady operating accumulation and warrants further scrutiny.

Income StatementBalance SheetCash FlowRatios

LKFT Balance Sheet

Annual statement

LKFT Balance Sheet

Lakefront Biotherapeutics N.V. (LKFT) balance sheet — 22-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04
Total Current Assets2.29B3.08B--4.24B4.86B5.37B5.87B1.33B1.2B1.01B374.47M213.6M173.35M132.73M65.56M109.22M84.69M59.85M80.74M79.86M36.55M12.54M
Cash & Short-Term Investments2.22B3B--4.09B4.7B5.16B5.78B1.29B1.15B973.24M340.31M187.71M138.18M94.65M32.55M40.4M47.39M27.32M49.3M51.52M23.62M10.27M
Cash Only96.26M87.87M--508.12M2.23B2.14B1.86B1.29B1.15B973.24M340.31M187.71M138.18M94.65M32.55M40.4M47.39M27.32M49.3M51.52M23.62M10.27M
Short-Term Investments2.12B2.91B--3.59B2.47B3.03B3.92B000000000000000
Accounts Receivable54.24M53.2M--77.34M128.6M173.4M80.11M33.53M41.79M23.48M16.06M13.79M31.98M33.24M28.86M63.48M31.98M26.62M22.08M24.85M9.79M2.17M
Days Sales Outstanding21.4417.46--117.0296.81132.3935.0242.38120.0266.16148.1472.5984.7789.04109.85189.3125.41126.2122.22258317.78101.8
Inventory4.95M22.49M--52.92M20.57M355K255K276K279K300K325K281K249K204K502K1.44M1.82M3.57M4.95M3.5M3.14M98K
Days Inventory Outstanding94.58276.09--614.724.61K0.250.220.310.470.780.910.922.21.551.474.527.7946.9859.8765.38237.4927.77
Other Current Assets5.79M5.61M--12.03M9.3M33.91M4.44M4.1M3.83M10.19M17.76M11.81M820K2.51M877K3.9M3.5M2.34M4.42M000
Total Non-Current Assets1.07B327.06M--497.5M331.31M348.38M202.68M110.64M88.63M76.11M68.04M56.86M114.03M102.6M95.49M84.74M59.02M58.98M67.98M87.78M45.02M3.07M
Property, Plant & Equipment76.98M80.66M--154.25M137.51M103.38M66.05M23.14M16.69M14.96M13.78M10.09M19.52M18.1M19.52M23.89M19.29M20.29M22.91M25.96M9.4M2.63M
Fixed Asset Turnover15.81x13.79x--1.56x3.53x4.62x12.64x12.48x7.61x8.66x2.87x6.87x7.05x7.53x4.91x5.12x4.83x3.79x2.88x1.35x1.20x2.96x
Goodwill00--69.81M0000000039.24M37.67M38.88M42.38M33.75M33.75M33.95M35.56M29.48M0
Intangible Assets767.03M848K--146.35M60.1M67.57M24.93M3.63M2.5M1.02M1.55M2.02M7.83M9.43M10.62M13.53M3.48M4.16M6.09M17.84M4.87M447K
Long-Term Investments523.42M46.81M--008.95M11.28M6M1.75M000220K01.04M0000000
Other Non-Current Assets3.81M198.55M--125.72M129.66M164.01M96.22M75.36M65.7M58.17M50.98M44.46M42.65M35.7M23.27M1.28M807K772K4.67M7.68M1.27M0
Total Assets3.35B3.41B--4.73B5.19B5.72B6.07B1.44B1.29B1.08B442.51M270.47M287.37M235.33M161.06M193.96M143.71M118.82M148.72M167.65M81.56M15.61M
Asset Turnover0.28x0.33x--0.05x0.09x0.08x0.14x0.20x0.10x0.12x0.09x0.26x0.48x0.58x0.60x0.63x0.65x0.65x0.44x0.21x0.14x0.50x
Asset Growth %-16.87%----8.83%-9.17%-5.78%321.58%11.91%18.73%144.81%63.61%-5.88%22.12%46.12%-16.97%34.97%20.94%-20.1%-11.29%105.54%422.4%-
Total Current Liabilities49.15M152.86M--522.54M566.47M635.27M571.79M219.91M171.7M103.79M72.41M60.36M112.56M109.01M35.36M38.22M31.34M29.75M43.36M29.28M14.06M3.61M
Accounts Payable46.42M32.62M--133.3M134.3M171.32M142.51M68.04M47.12M31.21M29.11M29.34M29.36M22.09M18.07M22.01M15.13M13.43M13.29M25.43M9.57M2.77M
Days Payables Outstanding505.25400.41--1.55K30.09K119.41123.8276.9178.7281.6181.9296.4259.53167.3852.7669.2564.9176.46160.84475.21723.2783.84
Short-Term Debt1.29M0--0000000000000016K00394K0
Deferred Revenue (Current)97.56K32K--365.63M419.87M443.16M414.3M149.8M122.54M70.83M39.81M27.03M78.98M83.61M13.02M0000000
Other Current Liabilities1.12M117.5M--8.51M204K12.08M6.2M1K060K368K767K81K177K394K15.79M15.65M15.72M27.39M556K0842K
Current Ratio46.49x20.15x--8.11x8.58x8.45x10.26x6.04x6.98x9.70x5.17x3.54x1.54x1.22x1.85x2.86x2.70x2.01x1.86x2.73x2.60x3.48x
Quick Ratio46.39x20.00x--8.01x8.55x8.45x10.26x6.04x6.97x9.70x5.17x3.53x1.54x1.22x1.84x2.82x2.64x1.89x1.75x2.61x2.37x3.45x
Cash Conversion Cycle-389.24-106.86---816.51-25.39K13.23-88.58-34.2341.77-14.6767.13-22.89-172.57-76.7958.55124.5668.3-3.2821.25-151.83-167.93-654.27
Total Non-Current Liabilities13.7M17.79M--1.69B1.98B2.41B2.62B5.34M102.59M220.85M5.1M3.98M7.68M7.87M7.32M7.23M3.49M4.75M6.74M28.83M6.36M1.64M
Long-Term Debt00--0000000000000000000
Capital Lease Obligations16.67M5.19M--14.69M19.66M23.04M19.56M009K63K115K167K165K451K867K964K1.16M1.75M4.59M4.61M0
Deferred Tax Liabilities00--20.15M000000002.19M2.62M2.4M2.69M564K201K292K594K1.54M225K
Other Non-Current Liabilities11.85M12.6M--27.35M18.83M23.09M15.25M5.34M5.24M6.05M5.04M3.86M5.32M5.08M4.46M3.67M1.96M3.39M4.7M23.64M214K1.41M
Total Liabilities62.85M170.65M--2.21B2.55B3.05B3.19B225.25M274.29M324.64M77.52M64.33M120.24M116.88M42.68M45.45M34.83M34.5M50.1M58.1M20.43M5.25M
Total Debt3.15M6.92M--21.9M26.86M29.44M25.38M09K63K115K167K393K405K876K1.25M1.48M1.7M4.37M7.77M7.97M0
Net Debt-93.1M-80.95M---486.22M-2.21B-2.11B-1.84B-1.29B-1.15B-973.18M-340.2M-187.54M-137.78M-94.24M-31.68M-39.15M-45.91M-25.61M-44.93M-43.75M-15.65M-10.27M
Debt / Equity0.00x0.00x--0.01x0.01x0.01x0.01x-0.00x0.00x0.00x0.00x0.00x0.00x0.01x0.01x0.01x0.02x0.04x0.07x0.13x-
Debt / EBITDA0.01x0.01x-----0.07x------0.17x-0.10x0.17x-----
Net Debt / EBITDA-0.19x-0.15x------4.91x-------39.28x--3.09x-5.33x-----
Interest Coverage4011.63x136.71x-2.39x4.18x-6.74x-10.54x-15.42x199.92x-39.28x-122.40x-244.47x-472.97x-319.01x-101.78x-33.35x-20.34x1.38x3.37x-1.80x-12.43x-10.82x-17.02x-21.02x
Total Equity3.29B3.24B--2.53B2.64B2.67B2.88B1.21B1.01B758.7M365M206.13M167.14M118.45M118.38M148.51M108.88M84.32M98.63M109.54M61.14M10.37M
Equity Growth %57.41%----4.44%-1.01%-7.14%136.83%19.99%33.38%107.86%77.07%23.33%41.11%0.06%-20.29%36.4%29.12%-14.5%-9.97%79.18%489.72%-
Book Value per Share50.0749.10--38.4540.3641.0449.9123.3020.4516.6010.226.855.814.464.486.125.033.984.778.096.841.75
Total Shareholders' Equity3.29B3.24B--2.53B2.64B2.67B2.88B1.21B1.01B758.7M365M206.13M167.14M118.45M118.38M148.51M108.88M84.32M98.63M109.54M61.14M10.37M
Common Stock298.91M293.94M--293.6M292.07M291.31M287.28M236.54M233.41M223.93M185.4M157.27M154.54M139.35M137.46M137.12M122.87M110.86M110.86M104.4M69.05M31.56M
Retained Earnings243.42M210.58M---496.69M-367.2M-334.7M-109.22M-297.78M-211.44M-112.27M-177.32M-63.94M-100.11M-94.77M-91.14M-60.08M-66.87M-72.49M-58.96M-39.03M-27.73M-21.19M
Treasury Stock-43.32M0--0000000000000000000
Accumulated OCI5.15M-5.64M---6.45M-11.9M-14.1M-5.98M-2.29M-3.01M-2.09M-485K-1.38M217K994K35K71.46M52.88M45.96M46.73M44.18M19.82M0
Minority Interest00--0000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Thin cash against persistent burn

Equity Base Rebuilt Through Reported Gains

According to reported quarterly figures, LKFT's equity rose from $2.4B in 2025Q3 to $3.3B in 2026Q3 while total liabilities fell from $1.1B to $62.9M, indicating a sharp deleveraging that appears tied to the 2025Q4 earnings spike rather than steady operating accumulation.

The shift in equity is driven by retained earnings moving from a deficit of $577.7M to a positive $243.4M, a change that depends heavily on the one-time $782.1M net income in 2025Q4. Because the surrounding quarters show operating losses, the improved balance sheet may reflect a non-recurring event rather than a durable strengthening of the business. Investors should monitor whether retained earnings can stay positive without a repeat of that gain.

Liquidity Ratios Mask Thin Cash Cushion

As reported in financial statements, LKFT's current ratio of 46.49 in 2026Q3 looks exceptionally strong, but cash of $96.3M against quarterly operating cash outflows near $33M to $83M implies a runway that is short relative to burn.

The very high current ratio largely reflects the small liability base after the 2025 restructuring of obligations, not a deep pool of liquid resources. Cash fell from $135.9M in 2026Q2 to $96.3M in 2026Q3 while buybacks continued, which suggests the company is drawing down its cash buffer. This warrants further investigation into how management plans to fund operations without new financing.

Share Repurchases Drawing on Thin Reserves

Based on LKFT's reported figures, the company deployed $38.1M into share repurchases in 2026Q3 while operating cash flow was negative $32.9M, a pattern that may indicate capital returns are funded from balance sheet cash rather than internally generated resources.

Repurchasing stock while operating cash flow is negative runs against the company's reported need to preserve liquidity, and it reduces cash that would otherwise extend the runway. The equity base is also heavily influenced by the non-operating gain in 2025Q4, so per-share value support from buybacks depends on that base being durable. Shareholders should weigh whether these repurchases are a responsible use of constrained resources.

Goodwill Dominates an Asset-Light Base

As reported in the filings, goodwill of $767.0M represents roughly 23% of LKFT's $3.4B total assets in 2026Q3, while net PP&E of $77.0M is small, pointing to an asset base concentrated in intangibles rather than physical capacity.

The large goodwill balance, which rose from $746.0K in 2026Q1 to $767.0M in 2026Q3, indicates a material acquisition or reclassification that the reported data does not explain. Because goodwill is subject to impairment testing, a write-down would hit equity directly and could reverse the retained earnings recovery. Investors should treat the headline asset total with caution given how much of it rests on this single intangible line.

Headline Deleveraging Rests on One Quarter

The strongest challenge to LKFT's balance sheet improvement is that the 2025Q4 net income of $782.1M, which drove the recovery in equity, coincided with $47.5M of operating cash outflow, suggesting the headline strength may not reflect cash generation.

Reported accounting gains can restore equity and shrink liabilities without any corresponding change in cash profile, which is what the figures appear to show. With free cash flow still deeply negative in recent quarters, the apparent balance sheet repair may be an accounting outcome rather than evidence of financial resilience. This distortion warrants close scrutiny before treating the current equity and low debt position as a stable foundation.

LKFT — Frequently Asked Questions

Quick answers to the most common questions about buying LKFT stock.

What are the total assets of Lakefront Biotherapeutics N.V. (LKFT)?

As of 2025, Lakefront Biotherapeutics N.V. (LKFT) had total assets of $3.41B including $3.08B in current assets.

How much debt does Lakefront Biotherapeutics N.V. (LKFT) have?

Lakefront Biotherapeutics N.V. (LKFT) carries total debt of $6.9M, offset by $3.00B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Lakefront Biotherapeutics N.V.?

Lakefront Biotherapeutics N.V. (LKFT) has total shareholders' equity (book value) of $3.24B ($49.10 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Lakefront Biotherapeutics N.V.'s current ratio and liquidity?

Lakefront Biotherapeutics N.V. (LKFT) reported a current ratio of 20.15x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.